StockData

Alumis vs Praxis Precision Medicines

ALMS and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and PRAX compare

Praxis Precision Medicines is the larger company, worth 13 times as much as Alumis ($8.7B against $665M).

Praxis Precision Medicines scores higher on the StockData Score (7 against 6 for Alumis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSPRAX
Size and price
Market cap$665M$8.7B
Share price$5.14$310.27
Change, 1 year−2.7%74.2%
Change, 5 years–23.4%
Beta (5Y)2.091.90
Employees224168
StockData Score
Total score67 (better)
Valuation score1 (better)0
Growth score00
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S89.9×–
P/B1.5× (better)6.5×
FCF yield−52.9%−3.5% (better)
Profitability
Operating margin−6204%–
Net margin−5933%–
FCF margin−4755%–
Return on equity−93.6%−38.9% (better)
Financial health
Debt / equity0.000.00
Current ratio6.7415.73 (better)
Altman Z-score−0.91104.35 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%121%
Held by insiders30.5%0.72%
Insider net buying, 12 months$44.7M (better)−$3.6M
Short interest, % of float12.3%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.